156 related articles for article (PubMed ID: 23842115)
1. Defective decatenation checkpoint function is a common feature of melanoma.
Brooks K; Chia KM; Spoerri L; Mukhopadhyay P; Wigan M; Stark M; Pavey S; Gabrielli B
J Invest Dermatol; 2014 Jan; 134(1):150-158. PubMed ID: 23842115
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
3. A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma.
Spoerri L; Brooks K; Chia K; Grossman G; Ellis JJ; Dahmer-Heath M; Škalamera D; Pavey S; Burmeister B; Gabrielli B
Pigment Cell Melanoma Res; 2016 May; 29(3):329-39. PubMed ID: 26854966
[TBL] [Abstract][Full Text] [Related]
4. Decatenation checkpoint-defective melanomas are dependent on PI3K for survival.
Brooks K; Ranall M; Spoerri L; Stevenson A; Gunasingh G; Pavey S; Meunier F; Gonda TJ; Gabrielli B
Pigment Cell Melanoma Res; 2014 Sep; 27(5):813-21. PubMed ID: 24890688
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha controls the decatenation checkpoint.
Luo K; Yuan J; Chen J; Lou Z
Nat Cell Biol; 2009 Feb; 11(2):204-10. PubMed ID: 19098900
[TBL] [Abstract][Full Text] [Related]
6. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.
Nakagawa T; Hayashita Y; Maeno K; Masuda A; Sugito N; Osada H; Yanagisawa K; Ebi H; Shimokata K; Takahashi T
Cancer Res; 2004 Jul; 64(14):4826-32. PubMed ID: 15256452
[TBL] [Abstract][Full Text] [Related]
7. A UVR-induced G2-phase checkpoint response to ssDNA gaps produced by replication fork bypass of unrepaired lesions is defective in melanoma.
Wigan M; Pinder A; Giles N; Pavey S; Burgess A; Wong S; Sturm RA; Gabrielli B
J Invest Dermatol; 2012 Jun; 132(6):1681-8. PubMed ID: 22402442
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the topoisomerase II-dependent decatenation G2 checkpoint and checkpoint kinases in human cells.
Kaufmann WK
Methods Mol Biol; 2009; 582():155-66. PubMed ID: 19763949
[TBL] [Abstract][Full Text] [Related]
9. The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
Franchitto A; Oshima J; Pichierri P
Cancer Res; 2003 Jun; 63(12):3289-95. PubMed ID: 12810661
[TBL] [Abstract][Full Text] [Related]
10. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
[TBL] [Abstract][Full Text] [Related]
11. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
12. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
[TBL] [Abstract][Full Text] [Related]
13. Small molecule modulation of the human chromatid decatenation checkpoint.
Haggarty SJ; Koeller KM; Kau TR; Silver PA; Roberge M; Schreiber SL
Chem Biol; 2003 Dec; 10(12):1267-79. PubMed ID: 14700634
[TBL] [Abstract][Full Text] [Related]
14. Degradation of ATM-independent decatenation checkpoint function in human cells is secondary to inactivation of p53 and correlated with chromosomal destabilization.
Kaufmann WK; Campbell CB; Simpson DA; Deming PB; Filatov L; Galloway DA; Zhao XJ; Creighton AM; Downes CS
Cell Cycle; 2002; 1(3):210-9. PubMed ID: 12429935
[TBL] [Abstract][Full Text] [Related]
15. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.
Kaufmann WK; Nevis KR; Qu P; Ibrahim JG; Zhou T; Zhou Y; Simpson DA; Helms-Deaton J; Cordeiro-Stone M; Moore DT; Thomas NE; Hao H; Liu Z; Shields JM; Scott GA; Sharpless NE
J Invest Dermatol; 2008 Jan; 128(1):175-87. PubMed ID: 17597816
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle checkpoint function in bladder cancer.
Doherty SC; McKeown SR; McKelvey-Martin V; Downes CS; Atala A; Yoo JJ; Simpson DA; Kaufmann WK
J Natl Cancer Inst; 2003 Dec; 95(24):1859-68. PubMed ID: 14679155
[TBL] [Abstract][Full Text] [Related]
17. G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells.
Kalsbeek D; Golsteyn RM
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29113112
[TBL] [Abstract][Full Text] [Related]
18. MCPH1 Lack of Function Enhances Mitotic Cell Sensitivity Caused by Catalytic Inhibitors of Topo II.
Arroyo M; Sánchez A; Cañuelo A; Heredia-Molina RF; Martínez-Molina E; Clarke DJ; Marchal JA
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32276518
[TBL] [Abstract][Full Text] [Related]
19. The decatenation checkpoint.
Damelin M; Bestor TH
Br J Cancer; 2007 Jan; 96(2):201-5. PubMed ID: 17211475
[TBL] [Abstract][Full Text] [Related]
20. A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.
Carson C; Omolo B; Chu H; Zhou Y; Sambade MJ; Peters EC; Tompkins P; Simpson DA; Thomas NE; Fan C; Sarasin A; Dessen P; Shields JM; Ibrahim JG; Kaufmann WK
Pigment Cell Melanoma Res; 2012 Jul; 25(4):514-26. PubMed ID: 22540896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
